Articles

Galina Pogossovas primary role at Exactis is as a Clinical Trial Assistant (CTA). In this role, Galina assists the clinical operations team in updating and maintaining documentation relating to clinical trials.

Over the past couple of years, the U.S. Food and Drug Administration (FDA) has taken a hard-line stance against drug products that were approved under the accelerated approval pathway, but have not met their post-marketing or confirmatory trial commitments.

Dr. Suzan McNamara knew she was too young to die. At 31, she was diagnosed with a rare disease called Chronic Myeloid Leukemia (CML), and was given only three to five years to live.

In May 2016, Lee-Anne Pickard, a nurse with close to 20 years of experience in cancer research, was sent an article from the Montreal Gazette. It outlined how Exactis had set up a pan-Canadian network to collect samples from patients for molecular testing in the hopes of matching them to...

Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients – A Canadian Trial through the Exactis Network (NCT04564079) Karen Gambaro 1 , Maud Marques 1 , Andrea Hébert-Losier 1 , Suzan McNamara 1 ,...

Plenary themes under which authors will submit their abstracts: • Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY. Maud Marques 1 , Karen Gambaro 1 , Vincent Normandeau-Babin 1 , David Bouffard 1 , Ethan Hoang 1 , Suzan McNamara 1 , the Exactis...

Nous aimerions vous informer de l’évolution naturelle d'Exactis Innovation et de son leadership. De ce fait, nous sommes heureux d'annoncer la nomination de Dr Kostas Trakas à titre de PDG d'Exactis Innovation à compter du 1er février 2022.

Nous sommes heureux d’avoir été choisi parmi les 39 meilleures entreprises d’essais cliniques au Canada selon le site: https://beststartup.ca/Voici un résumé de l’article: This article showcases our top picks for the best Canada based Clinical Trials companies. These startups and companies are taking a variety of approaches to innovating the...

Since their initial description in 19481, small DNA fragments travelling in the non-cellular component of internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine2,3,4,5,6. Although its origins have been a topic of controversy, cell-free DNA (cfDNA) is generally thought to arise from cellular breakdown...

Exactis Innovation is a pan-Canadian research network that accelerates biomarker-led clinical and translational research in areas of high-unmet medical need. Precision Medicine in Cancer Care The past decade has seen the emergence of precision medicine, a complicated method of cancer treatment in which different molecular variants found in tumours guide...